Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2366-1089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors ; day:25 ; month:9 ; year:2017 ; pages:1-10
Oncology and Therapy ; (25.9.2017), 1-10
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Shen, Lin
- Beteiligte Personen und Organisationen
-
Sun, Yan
Xu, Jian-Ming
Linn, Carlos
Wang, Qiao
Yang, Li-Qiang
Qin, Shu-Kui
SpringerLink (Online service)
- DOI
-
10.1007/s40487-017-0052-4
- URN
-
urn:nbn:de:1111-201711223105
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shen, Lin
- Sun, Yan
- Xu, Jian-Ming
- Linn, Carlos
- Wang, Qiao
- Yang, Li-Qiang
- Qin, Shu-Kui
- SpringerLink (Online service)
Ähnliche Objekte (12)
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
Positive solutions for one-dimensional third-order p-Laplacian boundary value problems
Regorafenib bei GIST : neuer Therapie-Standard bei Progress nach Imatinib und Sunitinib
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
Economic Opportunities and Gender Equity: The Migration and Education Decisions of Young Women from Rural China
Bi-objective optimization for multi-modal transportation routing planning problem based on Pareto optimality
Dynamic Bayesian network modeling for intervention mechanism
Learning Bayesian network structure based on the classification and regression tree
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
Positive solutions for one-dimensional third-order p-Laplacian boundary value problems
Regorafenib bei GIST : neuer Therapie-Standard bei Progress nach Imatinib und Sunitinib
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
Economic Opportunities and Gender Equity: The Migration and Education Decisions of Young Women from Rural China
Bi-objective optimization for multi-modal transportation routing planning problem based on Pareto optimality
Dynamic Bayesian network modeling for intervention mechanism
Learning Bayesian network structure based on the classification and regression tree
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
Positive solutions for one-dimensional third-order p-Laplacian boundary value problems
Regorafenib bei GIST : neuer Therapie-Standard bei Progress nach Imatinib und Sunitinib
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
Economic Opportunities and Gender Equity: The Migration and Education Decisions of Young Women from Rural China
Bi-objective optimization for multi-modal transportation routing planning problem based on Pareto optimality
Dynamic Bayesian network modeling for intervention mechanism